9788418892912. Manual de psiquiatría clínica_5ed

276

Kaplan & Sadock. Manual de psiquiatría clínica

Lewin AB, Piacentini J. Obsessive-compulsive disorder in children. In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock’s Comprehen sive Textbook of Psychiatry . 9th ed. Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:3671. Masi G, Pfanner C, Millepiedi S, Berloffa S. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol . 2010;30:688–693. Micali N, Hayman I, Perez M, Hilton K, Nakatani E, Turner C, Mataiz-Cois D. Long-term outcomes of obsessive-compulsive disor der: follow-up of 142 children and adolescents. Br J Psychiatry . 2010;197:128–134. Olino TM, Gillo S, Rowe D, Palermo S, Nuhfer EC, Birmaher B, Gilbert AR. Evidence for successful implementation of exposure and response prevention in a naturalistic group format for pediatric OCD. Depress Anxiety . 2011;4:342–348. Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, ser traline, and their combination for children and adolescents with obses sive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA . 2004;292:1969. Piacentini J, Bergman RL, Chang S, Langley A, Peris T, Wood JJ, McCracken J. Controlled comparison of family cognitive behavio ral therapy and psychoeducation/relaxation training for child obses sive-compulsive disorder. J Am Acad Child Adolesc Psychiatry . 2011;50:1149–1161. Radua J, Mataiz-Cois D. Voxel-wise meta-analysis of grey matter chan ges in obsessive-compulsive disorder. Br J Psychiatry . 2009;195: 393–402. Rotge JY, Langbour N, Guehl D, Bioulac B, Jaafari N, Allard M, Aoui zerate B, Burbaud P. Gray matter alterations in obsessive-compulsive disorder: an anatomical likelihood estimation meta-analysis. Neuropsy chopharmacology . 2010;35:686–691. Storch EA, Caporino NE, Morgan JR, Lewin AB, Rojas A, Brauer L, Lar son MJ, Murphy TK. Preliminary investigation of web-camera delive red cognitive-behavioral therapy for youth with obsessive-compulsive disorder. Psychiatry Res . 2011;189:407–412. Szeszko PR, MacMillan S, McMeniman M, Chen S, Baribault K, Lim KO, Ivey J, Rose M, Banerjee SP, Bhandari R, Moore GJ, Rosenberg DR. Brain structural abnormalities in psychotropic drug-naive pedia tric patients with obsessive-compulsive disorder. Am J Psychiatry . 2004;161:1049–1056. Waslick B. Psychopharmacology intervention for pediatric anxiety disor ders: a research update. Child Adolesc Psychiatr Clin N Am . 2006;1:51.

Double-blind maintenance safety and effectiveness findings from the treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. J Am Acad Child Adolesc Psychiatry . 2010;49:583–594. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH. A multiple-center, rando mized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry . 2008;165:1432–1441. Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lie berman JA, Hooper SR. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry . 2012;51:496–505. Fusar-Poli P, Bechdolf A, Taylor M, Carpenter W, Yung A, McGuire P. At risk for schizophrenia or affective psychosis? Ameta-analysis of DSM/ ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull . 2013;39:923–932. Fusar-Poli P, Bonoldi I, Yung AR. Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychia try . 2012;69:220–229. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkö tter J, McGuire P, Yung A. The psychosis high-risk state. A compre hensive state-of-the-art review. JAMA Psychiatry . 2013;70:107–120. Gentile S. Clinical usefulness of second-generation antipsychotics in trea ting children and adolescents diagnosed with bipolar or schizophrenic disorders. Pediatr Drugs . 2011;13:291–302. Haas M, Eerdekens M, Kushner SF, Singer J, Augustyns I, Quiroz J, Pandina G, Kusumakar V. Efficacy, safety and tolerability of two ris peridone dosing regimens in adolescent schizophrenia: a double-blind study. Br J Psychiatry . 2009;194:158–164. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week randomized double-blind placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol . 2009;19:611–621. Jacobs E, Kline E, Schiffman J. Defining treatment as usual for attenua ted psychosis syndrome: a survey of community practitioners. Psychiatr Serv . 2012;63:1252–1256. Jacquet H, Rapoport JL, Hecketsweiler B, Bobb A, Thibaut F, Frebourg T, Campion D. Hyperprolinemia is not associated with childhood onset schizophrenia. Am J Med Genet B Neuropsychiatr Genet . 2006;141:192. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry . 2009;48:60–70. Kumra S, Kranzler H, Gerbine-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll C, Kane J. Clozapine and ‘high-dose’ olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry . 2008;63:524–529. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lin dborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry . 2006;163:790–799.

Trastornos psicóticos

Addington J, Epstein I, Liu L, French P, Boydell KM. A randomized con trolled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res . 2011;125:54–61. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM. Long-chain w-3 fatty acids for indicated prevention of psychotic disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry . 2010;67:146–154. Arango C. Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry. Eur Child Adolesc Psychiatry . 2011;20:67–70. Bechdolf A, Wagner M, Ruhrman S, Harrigan S, Putzfeld V, Pukrop R, Brockhaus-Dumke A, Berning J, Janssen B, Decker P, Bottlender R, Maurer K, Möller HJ, Gaebel W, Häfner H, Maier W, Klosterkötter J. Preventing progression to first episode psychosis in early initial prodro mal states. Br J Psychiatry . 2012;200:22–29. Biswas P, Malhotra S, Malhotra A, Gupta N. Comparative study of neu ropsychological correlates in schizophrenia with childhood onset, ado lescence and adulthood. Eur Child Adolesc Psychiatry . 2006;15:360. Clark C, Narr KL, O’Neill J, Levitt J, Siddarth P, Phillips O, Toga A, Caplan R. White matter integrity, language, and childhood onset schi zophrenia. Schizophrenia Res . 2012;138:150–156. Correll CU. Symptomatic presentation and initial treatment for schi zophrenia in children and adolescents. J Clin Psychiatry . 2010;71:11. David CN, Greenstein D, Clasen L, Gochman P, Miller R, Tossell JW, Mattai AA, Gogtay N, Rapoport JL. Childhood onset schizophrenia: high rate of visual hallucinations. J Am Acad Child Adolesc Psychiatry . 2011;50:681–686. Fagerlund B, Pagsberg AK, Hemmingsen RP. Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders. Schizophr Res . 2006;85(1–3):30. Findling RL, Johnson JL, McCLellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rössler A, Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EY, Keshavan MS, Yung AR. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry . 2009;70:1206–1212. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Ran domized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthres hold symptoms. Arch Gen Psychiatry . 2002;59:921–928. McGurk SR, Twamlety EW, Sitezer DL, McHugo JG, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychia try . 2007;164:1791–1802. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall R. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychia try . 2004;185:291–297. Peterson L, Jeppesen P, Thorup A, Abel MB, Øhlenschlaeger J, Christen son TØ, Krarup G, Jørgensen P, Nordentoft M. A randomised multicen tre trial of integrated verus standard treatment of patients with a first episode of psychotic illness. BMJ . 2005;331:602. SAMPLE